The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1594-1596

  Tousoulis, Dimitris ^a   Siasos, Gerasimos ^a   Zaromitidou, Marina ^a   Oikonomou, Evangelos ^a   Maniatis, Konstantinos ^a   Kioufis, Stamatios ^a   Kokkou, Eleni ^a   Papavassiliou, Athanasios G ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clopidogrel; Coronary artery disease; Platelet function; Polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; PROTON PUMP INHIBITOR;

ADULT; ANGIOCARDIOGRAPHY; BLEEDING; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CYP2C19 GENE; DISEASE SEVERITY; DNA EXTRACTION; FEMALE; FOLLOW UP; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; HYPOVOLEMIA; LETTER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLATELET REACTIVITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REGULATORY MECHANISM; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK;

CLOPIDOGREL; CORONARY ARTERY DISEASE; PLATELET FUNCTION; POLYMORPHISM;

AGED; ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84885295315     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.040     Document Type: Article

References (9)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel In addition to aspirin In patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
2. Heitzer T, Rudolph V, Schwedhelm E, et al. Clopidogrel Improves systemic endothelial nitric oxide bioavailability In patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006;26:1648-52.
3. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability In Individual responsiveness to clopidogrel: clinical Implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-16.
4. Tousoulis D, Siasos G, Zaromytidou M, et al. The role of the cytochrome P450 polymorphisms In clopidogrel efficacy and clinical utility. Curr Med Chem 2011;18:427-38.
5. Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2013;167(5):1924-8.
6. Parodi G, Marcucci R, Valenti R, et al. high residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCi. JAMA 2011;306:1215-23.
7. Siasos G, Tousoulis D, Stefanadis C. CYP2C19 genotype and cardiovascular events. JAMA 2012;307:1483-4.
8. Mega JL, Close SL,Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
9. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704-14.